Cancer Tubulin Inhibitors Market By Product ( Docetaxel, Trastuzumab Emtansine, Abraxane, Brentuximab Vedotin, Cabazitaxel ), By Application ( Non-Small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Colorectal Cancer, Ovarian Cancer ), Industry Trends, Estimation & Forecast, 2017 - 2025

Check Today's Best Price

$3500 Buy Now
Cancer Tubulin Inhibitors Market is expected to grow with a CAGR of xx% during the forecast period of 2018 to 2025.
  • Market Overview:

    Tubulin is a globular protein, which polymerizes into α- and β-tubulins acting as a major component of eukaryotic cytoskeleton. Microtubules are extremely important for the execution of cellular activities such as cellular trafficking, mitosis and cell proliferation. However, excessive amplification of mitosis coupled with complicated and abnormal cellular activities can lead to the emergence of cancer developing origins. Tubulin inhibitors such as Docetaxel and Abraxane have been found highly efficient in targeting the taxane and vinca binding sites which avoids further clustering in expansion of cancerous cells. Tubulin inhibitors work by interfering the microtubule dynamics either by inhibiting the polymerization or depolymerization.

    Tubulin inhibitors are well approved cancer drugs and are being deployed all over the world. Since the last decade, tubulin inhibitors have emerged out as a major cancer therapy and has become a point of focus due to ongoing researches in the field of micro biology. A continuous demand for developing and commercializing a novel and least penetrative mode of chemotherapeutics is propelling the growth of cancer tubulin inhibitors market. Moreover, a high rate of occurrence of breast and prostate cancer is contributing substantially in the increasing demand for tubulin inhibitors. However toxicity and problematic side effects caused by these inhibitors might act as a major hindrance in the growth of the very market.

    The report provides detailed qualitative and quantitative analysis of the Cancer Tubulin Inhibitors Market. Market size and forecast in terms of value and volume has been provided for the period – (2017 – 2025), for the segments namely type and application in each of the major regions.

    Cancer Tubulin Inhibitors Market Segmentation

    By Product 
    • Docetaxel
    • Trastuzumab Emtansine
    • Abraxane
    • Brentuximab Vedotin
    • Cabazitaxel

    By Application
    • Non-Small Cell Lung Cancer
    • Prostate Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Ovarian Cancer

    By Geography

     • North America
    o U.S.
    o Canada
    o Mexico

    • Europe
    o U.K.
    o France
    o Germany
    o Italy
    o Spain
    o Rest of Europe

     • Asia-Pacific
    o China
    o Japan
    o India
    o Korea
    o Rest of APAC

    • South America
    o Brazil
    o Rest of South America

    • Rest of the World
    o Middle East
    o Africa

    keyboard_arrow_up
  • CHAPTER 1. INTRODUCTION
    1.1. RESEARCH METHODOLOGY
    1.1.1. ERC desk research
    1.1.2. ERC data synthesis
    1.1.3. Data validation and market feedback
    1.1.4. ERC data sources

    CHAPTER 2. CANCER TUBULIN INHIBITORS MARKET OVERVIEW
    2.1. CANCER TUBULIN INHIBITORS MARKET INTRODUCTION
    2.2. GLOBAL CANCER TUBULIN INHIBITORS MARKET PRODUCTION AND GROWTH RATE, 2017-2025
    2.2.1. Global Cancer Tubulin Inhibitors Production (VOLUME) and Growth Rate (%), (2017-2025)
    2.3. GLOBAL CANCER TUBULIN INHIBITORS MARKET CAPACITY AND GROWTH RATE, 2017-2025
    2.3.1. Global Cancer Tubulin Inhibitors Capacity (VOLUME) and Growth Rate (%), (2017-2025)
    2.4. GLOBAL CANCER TUBULIN INHIBITORS MARKET REVENUE AND GROWTH RATE, 2017-2025
    2.4.1. Global Cancer Tubulin Inhibitors Market Revenue (Million USD) and Growth Rate (%), (2017-2025)
    2.5. GLOBAL CANCER TUBULIN INHIBITORS MARKET CONSUMPTION AND GROWTH RATE, 2017-2025
    2.5.1. Global Cancer Tubulin Inhibitors Consumption (VOLUME) and Growth Rate (%), (2017-2025)
    2.6. GLOBAL CANCER TUBULIN INHIBITORS MARKET PRICE TREND, 2017-2025
    2.6.1. Global Cancer Tubulin Inhibitors Market Price Trend and Growth Rate (%), (2017-2025)

    CHAPTER 3. GLOBAL CANCER TUBULIN INHIBITORS MARKET BY PRODUCT, 2017-2025
    3.1. DOCETAXEL
    3.2. TRASTUZUMAB EMTANSINE
    3.3. ABRAXANE
    3.4. GLOBAL CANCER TUBULIN INHIBITORS MARKET REVENUE BY PRODUCT, 2017-2025
    3.4.1. Global Cancer Tubulin Inhibitors Market Revenue (Million USD) and Share (%) By Product, 2017-2025
    3.4.2. Docetaxel Market Revenue and Growth Rate, 2017-2025
    3.4.3. Trastuzumab Emtansine Market Revenue and Growth Rate, 2017-2025
    3.4.4. Abraxane Market Revenue and Growth Rate, 2017-2025
    3.5. GLOBAL CANCER TUBULIN INHIBITORS MARKET PRODUCTION BY PRODUCT, 2017-2025
    3.5.1. Global Cancer Tubulin Inhibitors Market Production (Volume) and Share (%) By Product, 2017-2025
    3.5.2. Docetaxel Market Production and Growth Rate, 2017-2025
    3.5.3. Trastuzumab Emtansine Market Production and Growth Rate, 2017-2025
    3.5.4. Abraxane Market Production and Growth Rate, 2017-2025

    Note: Similar information coverage has been provided for other product segment.

    CHAPTER 4. GLOBAL CANCER TUBULIN INHIBITORS MARKET BY APPLICATION, 2017-2025
    4.1. NON-SMALL CELL LUNG CANCER
    4.2. PROSTATE CANCER
    4.3. BREAST CANCER
    4.4. GLOBAL CANCER TUBULIN INHIBITORS MARKET REVENUE BY APPLICATION, 2017-2025
    4.4.1. Global Cancer Tubulin Inhibitors Market Revenue (Million USD) and Share (%) By Application, 2017-2025
    4.4.2. Non-Small Cell Lung Cancer Market Revenue and Growth Rate, 2017-2025
    4.4.3. Prostate Cancer Market Revenue and Growth Rate, 2017-2025
    4.4.4. Breast Cancer Market Revenue and Growth Rate, 2017-2025 28
    4.5. GLOBAL CANCER TUBULIN INHIBITORS MARKET CONSUMPTION BY APPLICATION, 2017-2025
    4.5.1. Global Cancer Tubulin Inhibitors Market Consumption (Volume) and share (%) By Application, 2017-2025
    4.5.2. Non-Small Cell Lung Cancer Market Consumption and Growth Rate, 2017-2025
    4.5.3. Prostate Cancer Market Consumption and Growth Rate, 2017-2025
    4.5.4. Breast Cancer Market Consumption and Growth Rate, 2017-2025

    Note: Similar information coverage has been provided for other application segment.

    CHAPTER 5. GLOBAL CANCER TUBULIN INHIBITORS MARKET BY REGION, 2017-2025
    5.1. NORTH AMERICA
    5.1.1. U.S.
    5.1.2. Canada
    5.1.3. Mexico
    5.2. EUROPE
    5.2.1. U.K.
    5.2.2. France
    5.2.3. Germany
    5.2.4. Italy
    5.2.5. Spain
    5.2.6. Rest of Europe
    5.3. ASIA PACIFIC
    5.3.1. China
    5.3.2. Japan
    5.3.3. India
    5.3.4. Korea
    5.3.5. Rest of APAC
    5.4. SOUTH AMERICA
    5.4.1. Brazil
    5.4.2. Rest of South America
    5.5. REST OF THE WORLD
    5.5.1. Middle East
    5.5.2. Africa
    5.6. GLOBAL CANCER TUBULIN INHIBITORS MARKET REVENUE BY REGION, 2017-2025
    5.6.1. Global Cancer Tubulin Inhibitors Market Revenue (Million USD) and Share (%) By Region, 2017-2025
    5.6.2. North America Market Revenue and Growth Rate, 2017-2025
    5.6.3. Europe Market Revenue and Growth Rate, 2017-2025
    5.6.4. Asia Pacific Market Revenue and Growth Rate, 2017-2025
    5.6.5. South America Market Revenue and Growth Rate, 2017-2025
    5.6.6. Rest of the World Market Revenue and Growth Rate, 2017-2025

    CHAPTER 6. GLOBAL CANCER TUBULIN INHIBITORS MARKET PRODUCTION AND CONSUMPTION ANALYSIS BY REGION, 2017-2025
    6.1. GLOBAL CANCER TUBULIN INHIBITORS MARKET PRODUCTION ANALYSIS BY REGION, 2017-2025
    6.1.1. Global Cancer Tubulin Inhibitors Market Production (Volume) and Share (%) By Region, 2017-2025
    6.1.2. Global Cancer Tubulin Inhibitors Market Consumption (Volume) and Share (%) By Region, 2017-2025
    6.1.3. North America Market Production and Consumption, 2017-2025
    6.1.4. Europe Market Production and Consumption, 2017-2025
    6.1.5. Asia Pacific Market Production and Consumption, 2017-2025
    6.1.6. South America Market Production and Consumption, 2017-2025
    6.1.7. Rest of the World Market Production and Consumption, 2017-2025

    CHAPTER 7. MARKET DETERMINANTS
    7.1. MARKET DRIVERS
    7.2. MARKET RESTRAINTS
    7.3. MARKET OPPORTUNITIES
    7.4. MARKET DETERMINANTS RADAR CHART

    CHAPTER 8. GLOBAL CANCER TUBULIN INHIBITORS MARKET COMPETITION BY MANUFACTURERS
    8.1. GLOBAL CANCER TUBULIN INHIBITORS PRODUCTION AND SHARE BY MANUFACTURERS (2017-2025)
    8.1.1. Global Cancer Tubulin Inhibitors Production (VOLUME) and Share (%) by Manufacturers (2017-2025)
    8.2. GLOBAL CANCER TUBULIN INHIBITORS REVENUE AND SHARE BY MANUFACTURERS (2017-2025)
    8.2.1. Global Cancer Tubulin Inhibitors Revenue (Million USD) and Share (%) by Manufacturers (2017-2025)
    8.3. CANCER TUBULIN INHIBITORS MARKET COMPETITIVE SITUATION AND TRENDS
    8.3.1. Cancer Tubulin Inhibitors Market Share (%) of Top 3 Manufacturers
    8.3.2. Cancer Tubulin Inhibitors Market Share (%) of Top 5 Manufacturers

    CHAPTER 9. GLOBAL CANCER TUBULIN INHIBITORS MANUFACTURERS ANALYSIS
    9.1. ABRAXIS BIOSCIENCES
    9.1.1. Business Overview
    9.1.2. Company Basic Information
    9.1.3. Cancer Tubulin Inhibitors Product Details
    9.1.4. Abraxis Biosciences Cancer Tubulin Inhibitors Production, Revenue and Gross Margin
    9.2. AGENSYS
    9.2.1. Business Overview
    9.2.2. Company Basic Information
    9.2.3. Cancer Tubulin Inhibitors Product Details
    9.2.4. Agensys Cancer Tubulin Inhibitors Production, Revenue and Gross Margin
    9.3. AMGEN
    9.3.1. Business Overview
    9.3.2. Company Basic Information
    9.3.3. Cancer Tubulin Inhibitors Product Details
    9.3.4. Amgen Cancer Tubulin Inhibitors Production, Revenue and Gross Margin
    9.4. CELGENE
    9.4.1. Business Overview
    9.4.2. Company Basic Information
    9.4.3. Cancer Tubulin Inhibitors Product Details
    9.4.4. Celgene Cancer Tubulin Inhibitors Production, Revenue and Gross Margin
    9.5. EAGLE PHARMACEUTICALS
    9.5.1. Business Overview
    9.5.2. Company Basic Information
    9.5.3. Cancer Tubulin Inhibitors Product Details
    9.5.4. Eagle Pharmaceuticals Cancer Tubulin Inhibitors Production, Revenue and Gross Margin
    9.6. ENDOCYTE
    9.6.1. Business Overview
    9.6.2. Company Basic Information
    9.6.3. Cancer Tubulin Inhibitors Product Details
    9.6.4. Endocyte Cancer Tubulin Inhibitors Production, Revenue and Gross Margin
    9.7. GENENTECH
    9.7.1. Business Overview
    9.7.2. Company Basic Information
    9.7.3. Cancer Tubulin Inhibitors Product Details
    9.7.4. Genentech Cancer Tubulin Inhibitors Production, Revenue and Gross Margin
    9.8. IMMUNOGEN
    9.8.1. Business Overview
    9.8.2. Company Basic Information
    9.8.3. Cancer Tubulin Inhibitors Product Details
    9.8.4. Immunogen Cancer Tubulin Inhibitors Production, Revenue and Gross Margin
    9.9. MODRA PHARMACEUTICALS
    9.9.1. Business Overview
    9.9.2. Company Basic Information
    9.9.3. Cancer Tubulin Inhibitors Product Details
    9.9.4. Modra Pharmaceuticals Cancer Tubulin Inhibitors Production, Revenue and Gross Margin
    9.10. PIERRE FABRE
    9.10.1. Business Overview
    9.10.2. Company Basic Information
    9.10.3. Cancer Tubulin Inhibitors Product Details
    9.10.4. Pierre Fabre Cancer Tubulin Inhibitors Production, Revenue and Gross Margin

    CHAPTER 10. CANCER TUBULIN INHIBITORS MARKET VALUE CHAIN ANALYSIS
    10.1. CANCER TUBULIN INHIBITORS INDUSTRIAL CHAIN ANALYSIS
    10.2. CANCER TUBULIN INHIBITORS KEY RAW MATERIALS ANALYSIS
    10.2.1. Key Raw Materials
    10.2.2. Price Trend of Key Raw Materials
    10.2.3. Key Suppliers of Raw Materials
    10.3. MARKETING CHANNEL
    10.3.1. Direct Marketing
    10.3.2. Indirect Marketing
    10.3.3. Distributors/Traders
    10.4. CONSUMER ANALYSIS
    10.4.1. Consumer 1
    10.4.2. Consumer 2
    10.4.3. Consumer 3
    10.4.4. Consumer 4

    keyboard_arrow_up
  • • Abraxis Biosciences
    • Agensys
    • Amgen
    • Celgene
    • Eagle Pharmaceuticals
    • Endocyte
    • Genentech
    • Immunogen
    • Modra Pharmaceuticals
    • Pierre Fabre
    • Roche
    • Sanofi-Aventis
    • Seattle Genetics
    • Tocris Bioscience

    keyboard_arrow_up


    • Keep your personal detail safe with us. Privacy Policy
      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

What Information does this report contain?

• What was the market size of the Cancer Tubulin Inhibitors Market in 2017 and the expected market size by 2025, along with the growth rate?
• An in-depth analysis of the current impacting factors, opportunities and challenges/restraints in the market
• Which are the largest revenue generating products, services or regions and their comparative growth rate?
• Which technology is in trend and how would it evolve during the forecast period (2017 – 2025)?
• Which are the leading companies in the Cancer Tubulin Inhibitors Market and their competitive positioning basis their market share, product portfolio, strategic attempts and business focus?

CLIENTS